Caribou Biosciences IPO

Caribou Biosciences is a leading clinical-stage CRISPR genome editing biotechnology company developing an internal pipeline of off-the-shelf, genome-edited CAR-T and natural killer (NK) cell therapies.

Register for Details

For more details on financing and valuation for Caribou Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Caribou Biosciences's ticker symbol?


What is Caribou Biosciences's stock price?

4.78 as of 9/29/23

Learn more about Caribou Biosciences

Forge green plus iconForge green minus icon

What is Caribou Biosciences funding to date?

Caribou Biosciences has raised $41.55MM to date.
Forge green plus iconForge green minus icon

When was Caribou Biosciences founded?

Caribou Biosciences was founded in 2011.
Updated on: Jun 12, 2022